Navigation Links
NeurogesX Expands Commercial Operations Leadership Team
Date:11/5/2009

SAN MATEO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the expansion of its U.S. commercial operations team to include a Vice President of Sales, Senior Director of Marketing and Director of Commercial Operations.

  • Timothy Arendt has been named Vice President Sales. He will implement and manage the U.S. specialty sales force for Qutenza(TM).
  • Amy C. Cavers has joined NeurogesX as Senior Director of Marketing. She will be responsible for U.S. marketing and the development of physician, payer and patient strategies to support the anticipated launch of Qutenza.
  • Linda L. Schock has been appointed Director of Commercial Operations. She will play a critical role in creating commercial infrastructure and processes for the Qutenza launch, including establishing and managing distribution channels.

Anthony DiTonno, President and CEO, commented, "With our PDUFA date fast approaching, this is a truly exciting time at NeurogesX as we gear up for the potential U.S. commercial launch of Qutenza. Each of these new commercial team members has exceptional, highly relevant experiences that provide a wonderful complement to our strong NeurogesX team. These individuals are joining Christopher Panarites, Senior Director of Reimbursement, to round out our commercial operations management team under Michael Markels, our Vice President of Commercial Operations and Business Development. They will all be instrumental in helping us execute a successful U.S. launch of Qutenza."

Mr. Arendt has 20 years of pharmaceutical marketing and sales experience. Prior to his arrival at NeurogesX, Mr. Arendt was Vice President, Sales at Xanodyne
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... DENVER , June 18, 2013  Healthgrades, ... evaluate, compare and connect with physicians and hospitals, ... 2013: "Lean in" When Making Healthcare Decisions to ... the best performing hospitals for maternity care, gynecologic ... the treatment of women across 15 of the ...
(Date:6/18/2013)... Pharmaceuticals, Inc. (NASDAQ: ISIS ), the leader in ... corporate update in conjunction with its 2013 Annual Meeting of ... p.m. Pacific Time in Carlsbad, CA. ... 2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders (only ... p.m. – 3:15 p.m. Corporate Presentation – Stanley T. ...
(Date:6/17/2013)... -- DNAtrix Inc., experts in oncolytic virus development, today ... the company,s lead product, DNX-2401, at the Replicating Oncolytic ... on June 18, 2013. Dr. ... in the field of oncolytic virus therapy, will present ... TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY KNOWN ...
Breaking Medicine Technology:Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 2Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 3Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 4Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2
... , - Partnership With ... Patients in California, Idaho, Indiana, Iowa, Maryland,Michigan and Ohio ... a world leader in healthcare and,medical publishing and online ... nation,s fourth largest Catholic health,system with 44 hospitals across ...
... /PRNewswire/ -- JumpStart Inc., the Northeast ... of high growth early-stage businesses, announced a JumpStart ... LLC. A spinout of NDI Medical, the Highland ... commercializing a surgical handheld disposable nerve stimulator. ...
Cached Medicine Technology:Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 2Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 3Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States 4JumpStart Invests in Checkpoint Surgical 2JumpStart Invests in Checkpoint Surgical 3
(Date:6/18/2013)... As obesity rates sky rocket in the ... equipment during childbirth comes as no shock. Forceps are surgical ... when she is unable to do so herself and although ... higher rates of complication for both the mother and the ... mother and child, forceps births add to the pressure of ...
(Date:6/18/2013)... SEATTLE, WA—A Washington state resident filed ... claiming he fell ill with a hepatitis A infection ... blend. The complaint was filed in Snohomish County ... Seattle-based law firm that has filed 14 previous ... complaint, Brian Brothers consumed “Townsend Farms Organic Antioxidant Blend” ...
(Date:6/18/2013)... The Drug Delivery Partnering Terms and Agreements ... drug delivery partnering deals and agreements entered into by ... provides a detailed understanding and analysis of how and ... of deals are discovery or development stage whereby the ... license the license drug delivery technology. These deals tend ...
(Date:6/18/2013)... The Temp1000IS temperature data logger is ... be used to automatically record temperatures between -20 and ... comes with the serial number and device name engraved. ... separately) docking station and can be placed directly into ... of end-caps to download data. The small size of ...
(Date:6/18/2013)... 2013 Parker Waichman LLP , ... of victims injured by defective medical devices, reports that ... Infuse bone graft products are now available. Published this ... the two studies serve up two key findings: There ... Infuse and the traditional bone graft; and there is ...
Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3
... the fight against HIV and they must be given ... a new commentary published today in the journal Nature ... who are evaluating multiple candidate vaccines designed to prevent ... commit to sharing technology and expertise with those in ...
... Tufts University School of Medicine in collaboration with ... created a computer program called Pathogen Simulation (PathSim) ... in humans. David Thorley-Lawson, PhD, professor of pathology ... PathSim, laboratory methods, and clinical studies to provide ...
... MA- Mayor Michael R. Bloomberg of New York ... Julius B. Richmond Award, the highest honor given by ... of bold initiatives that recognize public health as a ... extraordinary leadership in protecting and promoting the health of ...
... is the latest American Chemical Society (ACS) News Service ... journals and Chemical & Engineering News. With more than,160,000 ... the individual journal, or the American Chemical Society, as ... #1 FOR IMMEDIATE RELEASE , , Excess female ...
... at the University of Pennsylvania School of Medicine have ... affecting the prognosis of patients with head and neck ... issue of CANCER. , The belief that a patients ... their cancer is one that has been prominent among ...
... 100,000 California seniors finds too few health tests , ... care received by vulnerable elderly Medicare, Medicaid patients is ... Researchers at the University of California, Los Angeles, used ... of Vulnerable Elders project to look at 43 specific ...
Cached Medicine News:Health News:Fight against HIV needs local scientists, say researchers 2Health News:Epstein-Barr: a virtual look at a vexing virus 2Health News:Bloomberg receives award for promotion of health in NYC and nation 2Health News:Bloomberg receives award for promotion of health in NYC and nation 3Health News:Bloomberg receives award for promotion of health in NYC and nation 4Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 2Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 3Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 4Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 5Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 6Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 7Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 8Health News:Penn researchers find emotional well-being has no influence on cancer survival 2Health News:Most Elderly Don't Get Good Medical Care: Study 2
VersaStep™ Reposable Sterilization Trays....
... The Open-Step™ single-use system device is comprised ... for creating each access port are also ... 12 mm locking cone with 12 mm ... sterile; The 12 mm locking cone ...
... device components are supplied sterile. , ,The ... supplied sterile in 2/3, 5, 7/8, 10 and ... combinations. They are used in conjunction with the ... radially Expandable Sleeve. The 5, 7/8, 10 and ...
... V2 RT single-use obturator has a sharp linear ... ,The Auto Suture™ VERSAPORT™ PLUS V2 RT single-use ... mm and 12 mm diameters with a shield ... mm short single-use obturators are not available with ...
Medicine Products: